TB-500 in Sweden: import rules explained

The short answer for Sweden is no: you cannot legally import TB-500 for personal use under current Swedish and EU rules. TB-500 has no marketing authorisation from Läkemedelsverket^[1], no EMA approval^[2], and falls under the unlicensed medicinal product definition in the Swedish Medicines Act (Läkemedelslagen 2015:1649) if presented with any therapeutic claim. It has also been on the WADA Prohibited List since 1 January 2018.^[3] This page explains what that means in practice for anyone asking from Sweden.

What TB-500 actually is

TB-500 refers to a synthetic heptapeptide fragment (Ac-LKKTETQ) that corresponds to amino acids 17 to 23 of thymosin beta-4 (Tβ4), a 43-residue protein present in most human and animal cells. Tβ4's best-characterised role is as the principal G-actin sequestering molecule in mammalian cells; by sequestering actin it supports cell migration, wound healing, and angiogenesis.^[4] The compound was first sequenced in 1981 and has since appeared in preclinical models of dermal, corneal, and cardiac repair. A 2026 review of injectable peptide therapies in sports medicine concluded that TB-500 and its precursor Tβ4 promoted angiogenesis and tissue repair in animal models, but that human orthopaedic data are lacking and the substance remains a banned substance in sport.^[5]

The only clinical-stage programme for any Tβ4 product is RGN-259, a topical 0.1% ophthalmic solution developed by RegeneRx for neurotrophic keratopathy. That formulation is applied to the eye surface, not injected systemically. It bears no resemblance to the grey-market vials labelled TB-500 that circulate in the fitness and recovery space. Vendors frequently do not specify whether a vial contains the AC-LKKTETQ heptapeptide (molecular weight approximately 889 g/mol) or full-length Tβ4 (approximately 4,963 g/mol). The two molecules differ analytically and would not be interchangeable in any dosing framework, if one existed.

The regulatory position in Sweden

Sweden is an EU member state and applies EU pharmaceutical law directly. All medicines marketed in Sweden must hold either an EMA centralised marketing authorisation or a national licence from Läkemedelsverket. Neither thymosin beta-4 nor TB-500 holds either authorisation.^[1][2] A substance presented with any claim that it treats, prevents, or cures a condition triggers the medicinal product definition under EU Directive 2001/83/EC and its Swedish transposition. Under that definition, TB-500 vials sold for recovery or tissue repair are unlicensed medicinal products, not supplements or research chemicals with a protected legal status. Selling unlicensed medicinal products in Sweden without authorisation is a criminal offence under the Medicines Act.

The same product definition applies to online orders shipped from outside the EU. A package labelled TB-500 and marketed for athletic recovery lands in the same legal category as any other unlicensed medicine. For context on how TB-500 compares with other peptides across the countries we cover, see the Sweden regulation hub.

The licensläkemedel route: why it does not apply

Sweden has a special-access route for unlicensed medicines called licensläkemedel. This covers situations where an authorised medicine does not exist for a specific patient's condition and a licensed physician applies to Läkemedelsverket for permission to use a product that is approved in another country. The route exists for genuine therapeutic gaps and requires a prescribing clinician, a named patient, and a product with at least one national marketing authorisation somewhere. TB-500 holds no marketing authorisation in any EEA country, the UK, or the US. See the TB-500 regulatory status summary for a country-by-country view. There is no licensed version to reference in a licensläkemedel application, and the route is not a path to lawful personal import.

Athletes and gym users sometimes frame this as a prescribing question. A Swedish physician cannot lawfully prescribe a product with no marketing authorisation in any reference country. Even if a clinician were sympathetic to a patient's interest in TB-500 for tendon or muscle recovery, there is no legal pathway that ends with an authorised supply.

What happens at the Swedish border

Tullverket, the Swedish customs authority, enforces EU customs rules on goods entering from outside the EU. Medicines ordered online from non-EU vendors and shipped to Swedish addresses are subject to customs inspection. An unlicensed medicine without a valid prescription or a Läkemedelsverket special-access permit can be seized. For shipments originating within the EU, free-movement-of-goods rules apply in principle, but member states retain the right to restrict imports of products that do not comply with national medicines law, and unlicensed medicines fall outside the free-movement protections that apply to authorised products.

In practice, small parcels from online vendors often pass through without inspection. That is a fact about customs resource constraints, not a statement about legality. A vial labelled TB-500 with any recovery or therapeutic language on the label is identifiable as an unlicensed medicine if inspected and is liable to seizure. Consignments that clear customs do not become lawful: they remain in a grey area. The personal-import exemption under Swedish law covers authorised prescription medicines carried by a traveller who holds a valid prescription, not commercial shipments of unapproved substances. TB-500 does not fit that exemption on either count.

Travellers returning from countries where TB-500 is available in a different regulatory environment should be aware that Swedish customs officers inspect goods on entry. The product classification does not change at the Swedish border. Importing a substance that would require a marketing authorisation to sell in Sweden is the same whether it arrives by post or in a suitcase.

The WADA prohibition and who it affects

Thymosin-β4 and its derivatives, including TB-500, were added to the WADA Prohibited List under section S2.3 (Peptide Hormones, Growth Factors and Related Substances) effective 1 January 2018.^[3] The prohibition applies both in competition and out of competition. TB-500 is classified as a non-Specified Substance, meaning sanctions sit at the higher end of the range: a first violation typically carries a four-year period of ineligibility, with limited scope for reduction. A 2025 review in Sports Medicine noted that athletes regularly use unapproved peptides without appreciating the anti-doping consequences,^[6] and that real-world sanctions have been issued. A Canadian athlete received a four-year ban after a positive test that included TB-500.

The WADA classification matters beyond elite sport. Many Swedish sports federations apply anti-doping rules to masters divisions and amateur categories. Anyone who is, or expects to become, subject to testing under Swedish Anti-Doping rules, any international federation, or a workplace screening programme should treat TB-500 as a disqualifying substance. The TB-500 peptide page covers the anti-doping history and the comparative position across sports governing bodies.

What we do not yet know

The human safety profile for systemically injected TB-500 is largely uncharacterised. No completed Phase 2 or Phase 3 trial has studied subcutaneous TB-500 for tendon, ligament, or muscle repair. The only randomised controlled trial for a Tβ4 product used a topical ophthalmic formulation in 18 patients. A 2024 laboratory study found that the wound-healing activity attributed to TB-500 in earlier literature may be due to a metabolite, Ac-LKKTE, rather than the parent compound itself,^[7] which complicates extrapolation from animal data to human outcomes. A 2026 review in the American Journal of Sports Medicine concluded that the indications, dosing, frequency, and duration of treatment for injectable peptides including TB-500 remain unknown and that significant further research is required before clinical recommendations can be made.^[5]

There is also a theoretical tumour-promotion signal in some preclinical cancer-cell work. Human relevance for chronic systemic use is uncharacterised because the systemic injection use-case has never been formally studied in people. The absence of data is not reassurance; it is the gap. Anyone considering TB-500 should discuss the unknown safety profile with a clinician who can weigh it against the specific clinical context.

Practical context for Swedish readers

Sweden enforces EU medicines law. TB-500 has no approved status anywhere in the EEA. The WADA prohibition adds a separate layer of risk for anyone who competes or expects to compete. The human evidence base for systemic TB-500 is thin: substantial preclinical data exists, one small ophthalmic RCT exists, and no systemic injection trial has reported a defensible safety or efficacy picture. Importing TB-500 into Sweden sits outside the personal-import rules that apply to authorised prescription medicines. For the evidence review and the cross-country regulatory comparison, see the TB-500 peptide page and the Sweden regulation overview. Consulting a licensed physician about approved alternatives for the underlying condition is the appropriate starting point.

This article is for educational and journalistic purposes only and does not constitute medical or legal advice. Regulatory status changes. Verify with Läkemedelsverket and a qualified professional before making any decision. PeptideMethods.com does not sell, distribute, or facilitate the sale of any peptide product.